| 000 | 01617 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517235809.0 | ||
| 264 | 0 | _c20180924 | |
| 008 | 201809s 0 0 eng d | ||
| 022 | _a1536-5964 | ||
| 024 | 7 |
_a10.1097/MD.0000000000012317 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYan, Qingying | |
| 245 | 0 | 0 |
_aAssociation between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer: A meta-analysis. _h[electronic resource] |
| 260 |
_bMedicine _cSep 2018 |
||
| 300 |
_ae12317 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Review | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 |
_aCetuximab _xtherapeutic use |
| 650 | 0 | 4 |
_aColon _xpathology |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOdds Ratio |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aReceptor, ErbB-3 _xmetabolism |
| 650 | 0 | 4 |
_aRectum _xpathology |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGuo, Kaibo | |
| 700 | 1 | _aFeng, Guan | |
| 700 | 1 | _aShan, Feiyu | |
| 700 | 1 | _aSun, Leitao | |
| 700 | 1 | _aZhang, Kai | |
| 700 | 1 | _aShen, Fengfei | |
| 700 | 1 | _aShen, Minhe | |
| 700 | 1 | _aRuan, Shanming | |
| 773 | 0 |
_tMedicine _gvol. 97 _gno. 37 _gp. e12317 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MD.0000000000012317 _zAvailable from publisher's website |
| 999 |
_c28833204 _d28833204 |
||